Unsubscribe
 
         
                 

  MTM Newsletter N° 16 - March 2016
               
   
Laboratory News
Compact News
Reference and Orientation Ranges
More is not better
DMSA oral - Bioavailability and dose-dependent metal excretion
Guide to Metal Toxicology
Combination treatments
Medical Workshops and Conferences
Conferences and Workshops 2016
Studies and Analyses
EDTA and TACT (Trial to Assess Chelation Therapy), second trial
               
                           
   
                 
Laboratory News

Compact News
We realize how precious time is, and how little time we have to read lengthy articles. Therefore, we summarize important news. Contact us for more information.

Reference and Orientation Ranges
We have updated existing ranges and added new Orientation Ranges for combination treatments such as ZnDTPA and DMPS.
This will allow a more precise evaluation and comparison of test results.

More is not better
We have statistically evaluated the hypothesis that more of a chelating substance increases urinary excretion values accordingly. From our data, we can postulate that this is not the case. We verified the following data supplied by Heyl, Berlin (manufacturer of Dimaval):

DMPS oral - Urinary Copper excretion
DMPS oral in mg/kg Copper excretion in %  
25 171
50 197  
100 235  

The manufacturer of Dimaval lists a bioavailability of about 50% for oral DMPS. This is in agreement with our urine data comparison of DMPS iv vs. DMPS oral.
The statistical evaluation of urine excretion data obtained after the intravenous application of 1 ampule DMPS (250mg active substance) vs 5 ampules DMPS (1250mg active substance), administered one after another at the same sitting, showed little effect. In fact, the median suggests that the application of more than one ampule DMPS provides no advantage. With the exception of copper, selenium, zinc and urine creatinine level, the median concentration for toxic elements in urine stayed the same or decreased slightly.

DMSA oral - Bioavailability and dose-dependent metal excretion
The bioavailability of a chelating substance is affected by the route of administration and the pH of the environment in which it circulates. International citations list the bioavailability of DMSA between 20 and 50%. We assume that gastrointestinal function is an important factor in determining an oral chelator’s bioavailability, its metal binding and urinary excretion. Oral chelators first find and bind metals located in the GI Tract, therefore fecal metal binding influences urinary metal excretion. GI ‘cleansing’ may have to come before a urine provocation or challenge test. Attention to pH seems warranted.

We compared urinary metal concentration of a 500mg oral dose with that of 1000mg and found little difference in metal excretion. See Table below

DMSA oral N = # of Tests Lead Mercury Copper Iron Zinc
500mg 169 12.0 3.7 57.8 15.8 700
1000mg 219 13.8 3.9 75.2 15.6 700
Median value in mcg/g Creatinine

Guide to Metal Toxicology
Our new German “Handbuch der Metall Toxikologie“, is a cookbook version of a chelation therapy textbook. It provides updated protocols for various chelating agents, statistical data indicating the efficacy of metal binding for each chelator, data based suggestions for treatment schedules based on provocation test results and practical treatment tips.

The English version ‘The Handbook of Metal Toxicology’ is available soon.

Combination treatments
There is no advantage in combining chelating agents with similar function (i.e. vicinal dithiol such as DMSA and DMPS) especially if applied in the same manner (i.e. oral).
When EDTA iv is combined with oral DMSA, the vascular and the GI tract are detoxified at the same time; however statistics involving urinary metal tests do not provide evidence that the combination treatment increased renal metal excretion more than the single administration of intravenous EDTA would. Fecal metal testing can provide answers regarding fecal detox.

                     
                         
   
                 
Medical Workshops and Conferences

International Conferences & Workshops 2016
03/06/2016 Seminar Melbourne
Update on Chelation, Diagnostics & Treatment

Melbourne, Australia (English)
03/08/2016 Seminar Brisbane
Update on Chelation, Diagnostics & Treatment

Brisbane, Australia (English)
03/09/2016 Seminar Sydney
Update on Chelation, Diagnostics & Treatment

Sydney, Australia (English)
04/09/2016 Nonmedical Seminar
Update on Chelation, Diagnostics & Treatment

Nuremberg, Germany (German)

Details and updates under:
http://www.microtraceminerals.com/en/workshops

 
                         
   
                 
Studies and Analyses

EDTA and TACT (Trial to Assess Chelation Therapy), second trial
The National Center for Complementary and Integrative Health (NCCIH) of the National Institutes of Health (NIH) has awarded $800,000 to Mount Sinai Medical Center of Florida and the Duke Clinical Research Institute to initiate a planning year for the second Trial to Assess Chelation Therapy (TACT2).
We suggest that the metal detoxification effect of EDTA is included in the study. EDTA chelation removes toxic metals from the vascular system, thereby reducing inflammation and increasing the blood flow - all of which can be documented.

 
     
If you have any questions please feel free to contact us.

We wish you a nice time.

Your

E.Blaurock-Busch and Team
 
     
                   
                                 
Subscribe I Unsubscribe I Comments
MTM Micro Trace Minerals GmbH - Director: Yvette Busch - Amtsgericht Nuernberg: HRB 21937 - Röhrenstrasse 20, 91217 Hersbruck, Germany - Phone: +49 9151-4332 - Email : service@microtraceminerals.com